Methods of screening for high-affinity, isoform-selective TGFβ1 inhibitors
US12252531B2 · kind B2 · utility
0Cited by
10References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 11, 2019 |
| Grant date | Mar 18, 2025 |
| Priority date | — |
| Expiry date | Mar 26, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2760/18234
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed herein are monoclonal antibodies and antigen-binding fragments thereof capable of selectively inhibiting TGFβ1 with high potency. Related compositions, methods and therapeutic use are also disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.